Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Azathioprin Orifarm

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Azatioprin Testmiljö

Azatioprin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.

  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.

  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.

  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.

  5. Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009;85:647-54.

  6. Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician 2007;53:409-12.

  7. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker Inc., New York and Basel. 1985.

  8. Polifka JE, Friedman JM. Teratogen update: Azathioprine and 6-mercaptopurine. Teratology 2002;65:240-61.

  9. Mona Akbari et al. Systematic Review and Meta-Analysis on the Effects of Thiopurines on Birth Outcomes From Female and Male Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2013 Jan;19(1):15-22.

  10. Kanis SL, de Lima-Karagiannis A, de Boer NKH, van der Woude CJ. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. Clin Gastroenterol Hepatol. 2017;15(8):1232-1241e1.

  11. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150(3):734-757e1.

  12. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE et al. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021;160(4):1131-1139.

  13. Jølving LR, Anru PL, Nielsen J, Friedman S, Nørgård BM. The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines. Aliment Pharmacol Ther. 2021;54(8):1061-1069.

  14. Nørgård BM, Nielsen J, Friedman S. In utero exposure to thiopurines/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark. Aliment Pharmacol Ther. 2020;52(5):829-842.

  15. Belizna C, Meroni PL, Shoenfeld Y, Devreese K, Alijotas-Reig J, Esteve-Valverde E et al. In utero exposure to Azathioprine in autoimmune disease Where do we stand?. Autoimmun Rev. 2020;19(9):102525.

  16. J M Davison, H Dellagrammatikas, J M Parkin. Maternal Azathioprine Therapy and Depressed Haemopoiesis in the Babies of Renal Allograft Patients. Br J Obstet Gynaecol. 1985 Mar;92(3):233-9.

  17. C Thomas, C Monteil-Ganiere, S Mirallié, C Hémont, C Dert, A Léger, C Joyau, D Caldari, M Audrain . A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. J Crohns Colitis. 2018;12(2):258-261.

  18. Coté CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974;85(3):324-8.

  19. DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr. 1984;105(4):625-8.

  20. Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014 Mar;63(3):451-7.

  21. Maruyama H, Tada K, Fujiwara T, Ota K, Kageyama M. Utility of maternal 6-thioguanine nucleotide levels in predicting neonatal pancytopenia. AJP Rep. 2013;3(1):25-8.

  22. FDA alerts health care professionals of pregnancy problems associated with thiopurines. FDA [www]. [updated 2024-04-29, cited 2024-11-12].

  23. Frank Wolf M, Sloma R, Akria L, Rimon E, Wiener Y, Carmiel Haggai M et al. Azathioprine and 6-mercaptopurine-induced intrahepatic cholestasis of pregnancy: Case report and review of the literature. Taiwan J Obstet Gynecol. 2023;62(5):761-764.

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.
  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.
  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.
  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.
  5. Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009;85:647-54.
  6. Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician 2007;53:409-12.
  7. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker Inc., New York and Basel. 1985.
  8. Polifka JE, Friedman JM. Teratogen update: Azathioprine and 6-mercaptopurine. Teratology 2002;65:240-61.
  9. Mona Akbari et al. Systematic Review and Meta-Analysis on the Effects of Thiopurines on Birth Outcomes From Female and Male Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2013 Jan;19(1):15-22.
  10. Kanis SL, de Lima-Karagiannis A, de Boer NKH, van der Woude CJ. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. Clin Gastroenterol Hepatol. 2017;15(8):1232-1241e1.
  11. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150(3):734-757e1.
  12. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE et al. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021;160(4):1131-1139.
  13. Jølving LR, Anru PL, Nielsen J, Friedman S, Nørgård BM. The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines. Aliment Pharmacol Ther. 2021;54(8):1061-1069.
  14. Nørgård BM, Nielsen J, Friedman S. In utero exposure to thiopurines/anti-TNF agents and long-term health outcomes during childhood and adolescence in Denmark. Aliment Pharmacol Ther. 2020;52(5):829-842.
  15. Belizna C, Meroni PL, Shoenfeld Y, Devreese K, Alijotas-Reig J, Esteve-Valverde E et al. In utero exposure to Azathioprine in autoimmune disease Where do we stand?. Autoimmun Rev. 2020;19(9):102525.
  16. J M Davison, H Dellagrammatikas, J M Parkin. Maternal Azathioprine Therapy and Depressed Haemopoiesis in the Babies of Renal Allograft Patients. Br J Obstet Gynaecol. 1985 Mar;92(3):233-9.
  17. C Thomas, C Monteil-Ganiere, S Mirallié, C Hémont, C Dert, A Léger, C Joyau, D Caldari, M Audrain . A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. J Crohns Colitis. 2018;12(2):258-261.
  18. Coté CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974;85(3):324-8.
  19. DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr. 1984;105(4):625-8.
  20. Jharap B, de Boer NK, Stokkers P, Hommes DW, Oldenburg B, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014 Mar;63(3):451-7.
  21. Maruyama H, Tada K, Fujiwara T, Ota K, Kageyama M. Utility of maternal 6-thioguanine nucleotide levels in predicting neonatal pancytopenia. AJP Rep. 2013;3(1):25-8.
  22. FDA alerts health care professionals of pregnancy problems associated with thiopurines. FDA [www]. [updated 2024-04-29, cited 2024-11-12].
  23. Frank Wolf M, Sloma R, Akria L, Rimon E, Wiener Y, Carmiel Haggai M et al. Azathioprine and 6-mercaptopurine-induced intrahepatic cholestasis of pregnancy: Case report and review of the literature. Taiwan J Obstet Gynecol. 2023;62(5):761-764.